FRA
CRSP icon

Front Row Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Front Row Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.37K Hold
134
– – ﹤0.01% 431
2025
Q4 		$7.03K Hold
134
– – ﹤0.01% 415
2025
Q3 		$8.69K Buy
134
+18
+16% +$1.03K ﹤0.01% 401
2025
Q2 		$5.64K Hold
116
– – ﹤0.01% 427
2025
Q1 		$3.95K Hold
116
– – ﹤0.01% 422
2024
Q4 		$4.57K Hold
116
– – ﹤0.01% 413
2024
Q3 		$5.45K Hold
116
– – ﹤0.01% 405
2024
Q2 		$6.26K Hold
116
– – ﹤0.01% 685
2024
Q1 		$7.91K Hold
116
– – ﹤0.01% 636
2023
Q4 		$7.26K Sell
116
-720
-86% -$39.8K ﹤0.01% 353
2023
Q3 		$37.9K Sell
836
-15,832
-95% -$818K 0.02% 264
2023
Q2 		$936K Sell
16,668
-600
-3% -$34K 0.42% 58
2023
Q1 		$781K Sell
17,268
-180
-1% -$8.74K 0.37% 61
2022
Q4 		$709K Sell
17,448
-1,405
-7% -$74.5K 0.37% 68
2022
Q3 		$1.23M Sell
18,853
-287
-1% -$20.8K 0.64% 52
2022
Q2 		$1.16M Sell
19,140
-20
-0.1% -$1.18K 0.57% 53
2022
Q1 		$1.2M Buy
19,160
+100
+0.5% +$6.28K 0.49% 58
2021
Q4 		$1.44M Buy
19,060
+1,294
+7% +$113K 0.54% 56
2021
Q3 		$1.99M Buy
17,766
+225
+1% +$28.3K 0.84% 38
2021
Q2 		$2.05M Buy
17,541
+1,043
+6% +$127K 0.84% 37
2021
Q1 		$2.01M Buy
16,498
+536
+3% +$80.9K 0.97% 35
2020
Q4 		$2.44M Sell
15,962
-195
-1% -$23K 1.25% 20
2020
Q3 		$1.96M Sell
16,157
-410
-2% -$36.4K 1.04% 31
2020
Q2 		$1.22M Sell
16,567
-205
-1% -$12K 0.76% 45
2020
Q1 		$825K Buy
16,772
+16,722
+33,444% +$863K 0.56% 52
2019
Q4 		$3K Hold
50
– – ﹤0.01% 704
2019
Q3 		$2K Hold
50
– – ﹤0.01% 774
2019
Q2 		$2K Hold
50
– – ﹤0.01% 815
2019
Q1 		$2K Buy
+50
New +$1.73K ﹤0.01% 813

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Front Row Advisors's CRSP Position: Q1 2026 in Review

Front Row Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 134 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

Front Row Advisors first reported a position in CRSP in Q1 2019 and has held it in 29 quarters since. The position peaked at $2.44M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Front Row Advisors held 134 shares of CRISPR Therapeutics worth $6.37K as of Q1 2026.
  • Front Row Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #431 holding.
  • Front Row Advisors first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Front Row Advisors's CRISPR Therapeutics position peaked at $2.44M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.